Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
NewsA new era for polycythemia vera treatment has arrived. Rusfertide (Mimrylo), a first-in-class hepcidin mimetic, received FDA approval in August 2026 and is now a Category 1 NCCN-recommended therapy for both low- and high-risk PV. Phase 3 VERIFY trial data show 77% of patients on rusfertide avoided phlebotomy versus 33% on placebo, with significant improvements in fatigue and quality of life.
A new standard of care is taking shape for polycythemia vera (PV). Rusfertide (Mimrylo), a first-in-class injectable hepcidin mimetic developed by Takeda, received FDA approval in August 2026 and has since been added to the NCCN Clinical Practice Guidelines as a Category 1 recommendation across both low- and high-risk PV — the only therapy to hold that distinction across both risk groups. The approval and guideline inclusion are grounded in data from the phase 3 VERIFY trial, now published in the Journal of Clinical Oncology.
How it works: PV patients overproduce red blood cells, and the standard fix — repeated therapeutic phlebotomy — worsens iron deficiency and perpetuates the cycle. Rusfertide mimics hepcidin, the master iron-regulating hormone, to restrict iron delivery to the bone marrow and curb erythropoiesis, offering more consistent hematocrit control without the burden of frequent clinic visits.
By the Numbers:
Why it matters: PV is a lifelong condition with a median survival of 15–20 years, making quality of life a central treatment goal. Rusfertide not only reduces the clinical burden of phlebotomy but also meaningfully improves patient-reported fatigue — the symptom patients say most impairs their daily lives. Its self-injectable, once-weekly format also promotes patient autonomy and reduces healthcare system dependence.